SCWorx (WORX)
Market Price (2/28/2026): $0.3332 | Market Cap: $2.8 MilSector: Health Care | Industry: Health Care Technology
SCWorx (WORX)
Market Price (2/28/2026): $0.3332Market Cap: $2.8 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% | Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -168% | Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -41% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -7.1% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -56% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 136% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -143% | ||
| High stock price volatilityVol 12M is 147% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 89% | ||
| Key risksWORX key risks include [1] substantial doubt about its ability to continue as a going concern due to recurring losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -168% |
| Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -41% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -7.1% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -56% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 136% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -143% |
| High stock price volatilityVol 12M is 147% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 89% |
| Key risksWORX key risks include [1] substantial doubt about its ability to continue as a going concern due to recurring losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
SCWorx (WORX) stock has gained about 10% since 10/31/2025 because of the following key factors:
1. Strategic Partnerships and Contract Expansion Bolstered Growth.
SCWorx announced significant business developments, including a new partner agreement on December 15, 2025, with a healthcare supply chain company focused on AI-powered payment process automation, leveraging SCWorx's data management capabilities. Additionally, on December 17, 2025, the company secured a new academic hospital customer, a 500-bed Midwest-based organization, for data cleansing and enrichment services. These announcements indicated an expanding market presence and new revenue opportunities. Furthermore, an agreement with an existing healthcare partner was renewed for a new three-year term, valued at approximately $1,692,000, representing a 113% increase from the previous contract.
2. Nasdaq Granted a Minimum Bid Price Compliance Extension.
On October 14, 2025, SCWorx received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement of $1.00 per share, setting a new deadline of April 6, 2026. This extension likely alleviated immediate concerns regarding potential delisting, providing the company with more time to address its stock price and offering a degree of stability to investors.
Show more
1. Strategic Partnerships and Contract Expansion Bolstered Growth.
SCWorx announced significant business developments, including a new partner agreement on December 15, 2025, with a healthcare supply chain company focused on AI-powered payment process automation, leveraging SCWorx's data management capabilities. Additionally, on December 17, 2025, the company secured a new academic hospital customer, a 500-bed Midwest-based organization, for data cleansing and enrichment services. These announcements indicated an expanding market presence and new revenue opportunities. Furthermore, an agreement with an existing healthcare partner was renewed for a new three-year term, valued at approximately $1,692,000, representing a 113% increase from the previous contract.
2. Nasdaq Granted a Minimum Bid Price Compliance Extension.
On October 14, 2025, SCWorx received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement of $1.00 per share, setting a new deadline of April 6, 2026. This extension likely alleviated immediate concerns regarding potential delisting, providing the company with more time to address its stock price and offering a degree of stability to investors.
Show more
Stock Movement Drivers
Fundamental Drivers
The 9.5% change in WORX stock from 10/31/2025 to 2/27/2026 was primarily driven by a 127.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.31 | 0.33 | 9.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | -1.9% |
| P/S Multiple | 0.4 | 1.0 | 127.4% |
| Shares Outstanding (Mil) | 4 | 8 | -50.9% |
| Cumulative Contribution | 9.5% |
Market Drivers
10/31/2025 to 2/27/2026| Return | Correlation | |
|---|---|---|
| WORX | 9.5% | |
| Market (SPY) | 0.6% | -5.5% |
| Sector (XLV) | 11.1% | 3.6% |
Fundamental Drivers
The -2.5% change in WORX stock from 7/31/2025 to 2/27/2026 was primarily driven by a -77.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.34 | 0.33 | -2.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | -3.9% |
| P/S Multiple | 0.2 | 1.0 | 347.8% |
| Shares Outstanding (Mil) | 2 | 8 | -77.3% |
| Cumulative Contribution | -2.5% |
Market Drivers
7/31/2025 to 2/27/2026| Return | Correlation | |
|---|---|---|
| WORX | -2.5% | |
| Market (SPY) | 8.8% | 3.8% |
| Sector (XLV) | 23.4% | 6.0% |
Fundamental Drivers
The -77.6% change in WORX stock from 1/31/2025 to 2/27/2026 was primarily driven by a -81.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2272026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.49 | 0.33 | -77.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | -13.6% |
| P/S Multiple | 0.7 | 1.0 | 41.5% |
| Shares Outstanding (Mil) | 2 | 8 | -81.6% |
| Cumulative Contribution | -77.6% |
Market Drivers
1/31/2025 to 2/27/2026| Return | Correlation | |
|---|---|---|
| WORX | -77.6% | |
| Market (SPY) | 15.0% | 21.1% |
| Sector (XLV) | 10.5% | 15.6% |
Fundamental Drivers
The -94.4% change in WORX stock from 1/31/2023 to 2/27/2026 was primarily driven by a -90.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2272026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.00 | 0.33 | -94.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 3 | -34.6% |
| P/S Multiple | 1.1 | 1.0 | -10.0% |
| Shares Outstanding (Mil) | 1 | 8 | -90.5% |
| Cumulative Contribution | -94.4% |
Market Drivers
1/31/2023 to 2/27/2026| Return | Correlation | |
|---|---|---|
| WORX | -94.4% | |
| Market (SPY) | 75.0% | 13.4% |
| Sector (XLV) | 25.7% | 12.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| WORX Return | -4% | -69% | -69% | -8% | -89% | 71% | -98% |
| Peers Return | 9% | -14% | -25% | 3% | -4% | -12% | -38% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| WORX Win Rate | 33% | 25% | 42% | 33% | 8% | 100% | |
| Peers Win Rate | 44% | 38% | 46% | 47% | 45% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| WORX Max Drawdown | -11% | -71% | -72% | -51% | -89% | -13% | |
| Peers Max Drawdown | -15% | -50% | -42% | -31% | -37% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: OMCL, MDRX, BEAT, VEEV, SOLV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/27/2026 (YTD)
How Low Can It Go
| Event | WORX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.1% | -25.4% |
| % Gain to Breakeven | 3372.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -91.5% | -33.9% |
| % Gain to Breakeven | 1069.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -97.3% | -19.8% |
| % Gain to Breakeven | 3579.4% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to OMCL, MDRX, BEAT, VEEV, SOLV
In The Past
SCWorx's stock fell -97.1% during the 2022 Inflation Shock from a high on 8/9/2021. A -97.1% loss requires a 3372.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About SCWorx (WORX)
SCWorx Corp. provides software solutions for the management of health care providers' foundational business applications in the United States. The company provides services related to repair, normalization, and interoperability of information, as well as big data analytics model that provides web portal for display, and reporting and analysis of the information contained within the data warehouse. It also offers various software solutions and services, such as virtualized item master file repair, expansion, and automation; electronic medical record management, a module that integrates the advanced data attributes created in the item master to the electronic medical records; charge description master management(CDM), a module, which assists healthcare providers by integrating the CDM data into the workflow of the hospitals purchasing systems; contract management, a module that assists healthcare providers to establish a contract management system and to provide care to patients; request for proposal automation solution; rebate management; ScanWorx, a mobile perioperative closed loop scanning solution; and data integration and warehousing, as well as solutions for integration of acquired businesses, which enable deployment of a virtual item master files. The company sells its solutions and services to hospitals and health systems through its distribution and reseller partnerships. In addition, it offers CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling rapid test kits for COVID-19; and personal protective equipment. SCWorx Corp. is based in New York, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies for SCWorx (WORX):
- SCWorx is like SAP for hospital supply chains.
- SCWorx is like Oracle for hospital inventory management.
AI Analysis | Feedback
- Data Cleansing and Normalization: Services designed to standardize, enrich, and improve the accuracy of healthcare supply chain data.
- Master Data Management (MDM): Services focused on creating and maintaining a single, accurate source of truth for critical supply chain information across an organization.
- Supply Chain Analytics: Services that provide insights and tools to analyze and optimize healthcare supply chain performance, efficiency, and cost savings.
- Contract and Spend Management: Services that assist healthcare organizations in managing supplier contracts and analyzing expenditures to identify savings opportunities.
AI Analysis | Feedback
SCWorx (WORX) primarily sells its services and solutions to other companies within the healthcare sector. Based on its latest available SEC filings (e.g., the 10-K for the fiscal year ended December 31, 2022, filed March 31, 2023), SCWorx reported extreme customer concentration. Specifically, the company stated that **one customer accounted for 92% of its total revenue for the year ended December 31, 2022, and one customer accounted for 95% for the year ended December 31, 2021.** However, SCWorx has **not publicly disclosed the names of these specific major customer companies** in its SEC filings or other readily accessible official communications. Therefore, their symbols cannot be provided. SCWorx generally serves:Healthcare Providers: These include hospitals, large health systems, and integrated delivery networks that utilize SCWorx's software and services for supply chain optimization, data management, contract management, and procure-to-pay solutions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Timothy A. Hannibal President & CEO
Mr. Hannibal is a seasoned technology executive and entrepreneur with nearly 30 years of experience in SaaS and cloud technology, driving revenue, go-to-market strategies, business development, and mergers and acquisitions. He joined SCWorx in January 2019, having previously been an employee at Primrose Solutions (the predecessor to SCWorx) since September 2016, where he oversaw marketing, sales, and operations. Mr. Hannibal founded and served as President and CEO of VaultLogix for thirteen years. VaultLogix, a private equity-sponsored SaaS company in the cloud backup industry, was later acquired by J2 Global, a publicly traded technology company.
Christopher J. Kohler Chief Financial Officer
Mr. Kohler possesses over 15 years of experience across various roles in the finance and accounting sectors. He is the founder and CEO of Kohler Consulting, Inc., established in 2012. Through this firm, Mr. Kohler provides outsourced CFO and advisory services to both private and public companies, with a particular focus on small-cap and start-up businesses.
Anders Ohlsson Chief Technology Officer
Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Before joining SCWorx, he held senior leadership positions at WideOrbit, where he was instrumental in developing scalable SaaS platforms and managed cross-functional teams to deliver enterprise-grade technology solutions.
AI Analysis | Feedback
Key Risks to SCWorx (WORX)
SCWorx (WORX), a micro-cap healthcare data management company, faces several significant risks to its business operations and financial viability. The most pressing concerns revolve around its ability to continue as a going concern, the threat of delisting from Nasdaq, and a substantial customer concentration risk.
- Ability to Continue as a Going Concern and Recurring Losses: SCWorx has a history of significant losses and negative cash flows from operations, leading its auditors to flag substantial doubt about the company's ability to continue as a going concern. For the trailing twelve months ending in late 2025, the company reported a net loss of approximately $3.89 million on revenue of just $2.78 million, with a net margin of -139.68%. The accumulated deficit stood at $25,858,697 as of December 31, 2022. These ongoing financial challenges indicate deep-seated issues in cost structure and revenue generation, and the company may require additional capital, which may not be available on acceptable terms.
- Nasdaq Delisting Threat: The company is under threat of delisting from the Nasdaq Capital Market. As of April 2025, SCWorx was non-compliant with Nasdaq's $1.00 minimum bid price rule, with its stock trading around $0.28 in October 2025. SCWorx has been granted an extension until April 6, 2026, to regain compliance by maintaining a closing bid price of $1.00 or more for at least ten consecutive business days. Failure to meet this requirement would result in delisting, severely impacting the stock's liquidity and investor confidence. The company has also faced compliance issues related to delayed financial filings.
- Customer Concentration Risk: SCWorx operates with a significant customer concentration problem, as its top three customers accounted for 51% of its revenue as of September 2025. The loss of even one of these major contracts could be catastrophic for the company's financial condition. While a recent positive development in October 2025 saw the renewal of an agreement with an existing healthcare partner for three additional years with a 113% increase in contract value, the overall reliance on a few key customers remains a substantial risk.
AI Analysis | Feedback
The increasing market penetration and sophistication of integrated, artificial intelligence (AI) and machine learning (ML)-driven healthcare supply chain platforms, exemplified by solutions like those offered by Syft (an Omnicell company). These platforms provide highly automated, real-time predictive analytics for demand forecasting, inventory optimization, and contract compliance that significantly surpass the capabilities of traditional data management and item master systems, posing a direct competitive threat to SCWorx's core offerings by potentially rendering them less efficient or obsolete.AI Analysis | Feedback
SCWorx (WORX) operates in the healthcare information technology sector, providing data management and analytics solutions to healthcare providers. Their primary products and services encompass virtualized item master file repair, electronic medical record management, big data analytics, data cleansing, standardization, enrichment, master data management, centralized vendor information, contract management, spend analytics, and revenue cycle management.
The addressable markets for SCWorx's main products and services are significant, particularly in North America and globally:
- U.S. Healthcare Analytics Market: This market was valued at approximately USD 6.43 billion in 2022 and is projected to reach USD 13.49 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 10.2% from 2023 to 2030. North America held a dominant share of the global healthcare analytics market, accounting for 47.59% in 2023. The global market size for healthcare analytics was valued at USD 22.38 billion in 2023 and is expected to grow to USD 145.81 billion by 2032.
- U.S. Big Data Analytics in Healthcare Market: This market in the U.S. was estimated at USD 20.56 billion in 2024 and is forecast to reach around USD 121.24 billion by 2034, demonstrating a CAGR of 19.41% from 2025 to 2034. Globally, the big data analytics in healthcare market was valued at USD 56.47 billion in 2024 and is projected to reach approximately USD 327.57 billion by 2034, with North America holding the largest market share of 52% in 2024.
- U.S. Healthcare Supply Chain Management Market: This market generated USD 738.6 million in revenue in 2023 and is anticipated to grow to USD 1,367.9 million by 2030, with a CAGR of 9.2% from 2024 to 2030. Within this market, the software segment is considered the most lucrative and fastest-growing. The global healthcare supply chain management market was valued at USD 3.73 billion in 2024 and is projected to reach USD 5.72 billion by 2033, with North America dominating the market share at 39.8% in 2024.
- Global Healthcare Supply Chain Software Market: This market was valued at USD 6.5 billion in 2023 and is expected to reach USD 13.7 billion by 2030, with a projected CAGR of 10.30%.
AI Analysis | Feedback
SCWorx (NASDAQ: WORX) is expected to drive future revenue growth over the next 2-3 years through several key strategies centered on expanding its market presence and enhancing its healthcare technology offerings.
- Expansion of Healthcare Contracts and Customer Base: A primary driver for SCWorx is the securing of additional agreements with hospitals and healthcare systems. The company recently renewed a three-year agreement with an existing healthcare partner, which included a 113% increase in contract value, representing approximately $1.69 million in total revenue over three years. This expansion with existing clients also involved the addition of enhanced services and a doubling of the data volume processed, indicating growth through increased utilization and platform scalability.
- Innovation in Healthcare Data Management Solutions, including AI-Powered Advancements: SCWorx is focusing on innovation in its data management solutions. The company's engagement in AI-powered advancements is seen as a factor contributing to its market valuation and is anticipated to open lucrative new revenue streams.
- Full Implementation and Growth of the SaaS Model: The complete adoption and expansion of its Software-as-a-Service (SaaS) model are considered critical for achieving revenue stability and potential stock price growth. The company's digital solutions segment is predicted by analysts to experience further growth.
- Strategic Partnerships and Diversification: Strategic partnerships are expected to contribute to revenue growth by fostering better-integrated solutions within the healthcare sector. Furthermore, SCWorx has indicated a strategy to diversify and expand its service offerings, as evidenced by its letter of intent to acquire an environmental services company.
AI Analysis | Feedback
Share Issuance
- SCWorx implemented a 1-for-15 reverse stock split, effective October 11, 2023, reducing the number of outstanding common shares from approximately 17.9 million to around 1.2 million.
- In settlement of a $502,000 judgment with Core IR, SCWorx agreed to issue shares of its common stock, with 159,776 shares issued on July 18, 2024, an additional 191,250 shares on March 14, 2025, and 180,000 shares on May 21, 2025, for the remaining obligation.
- The company completed an equity financing deal on November 19, 2024, selling 232,558 shares of common stock and warrants, which generated $200,000 in gross proceeds.
- SCWorx also entered into warrant inducement agreements around October 2025, resulting in approximately $721,574 in gross proceeds from the exercise of warrants for up to 2,064,000 shares of common stock.
Inbound Investments
- SCWorx raised $200,000 in gross proceeds from institutional investors through an equity financing deal completed on November 19, 2024.
- Between July 15, 2024, and January 17, 2025, the company issued an aggregate of $2,655,000 in senior secured convertible notes.
Outbound Investments
- In March 2020, SCWorx established Direct-Worx, LLC as a wholly-owned subsidiary.
Capital Expenditures
- SCWorx reported very low or negligible capital expenditures from 2021 through June 2025, with Property, Plant & Equipment values consistently near zero in its balance sheets for these periods.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| SCWorx Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to WORX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 41.10 |
| Mkt Cap | 1.2 |
| Rev LTM | 883 |
| Op Inc LTM | 8 |
| FCF LTM | 67 |
| FCF 3Y Avg | 62 |
| CFO LTM | 134 |
| CFO 3Y Avg | 91 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.3% |
| Rev Chg 3Y Avg | -8.1% |
| Rev Chg Q | 0.7% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Mgn LTM | 1.5% |
| Op Mgn 3Y Avg | 4.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 13.0% |
| CFO/Rev 3Y Avg | 15.5% |
| FCF/Rev LTM | 8.0% |
| FCF/Rev 3Y Avg | 11.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.2 |
| P/S | 1.5 |
| P/EBIT | 1.9 |
| P/E | 3.9 |
| P/CFO | 8.4 |
| Total Yield | -7.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -1.4% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.9% |
| 3M Rtn | 5.3% |
| 6M Rtn | 1.7% |
| 12M Rtn | -14.4% |
| 3Y Rtn | -40.5% |
| 1M Excs Rtn | -6.5% |
| 3M Excs Rtn | 4.4% |
| 6M Excs Rtn | -4.9% |
| 12M Excs Rtn | -31.3% |
| 3Y Excs Rtn | -113.0% |
Price Behavior
Price Behavior
| Market Price | $0.33 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/06/2016 | |
| Distance from 52W High | -66.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.23 | $0.32 |
| DMA Trend | down | down |
| Distance from DMA | 48.1% | 3.8% |
| 3M | 1YR | |
| Volatility | 150.8% | 147.1% |
| Downside Capture | 54.83 | 175.72 |
| Upside Capture | 241.13 | 43.07 |
| Correlation (SPY) | 0.3% | 20.9% |
WORX Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.02 | 0.92 | -0.54 | 0.78 | 1.72 | 1.48 |
| Up Beta | -17.67 | -9.64 | -1.31 | 0.45 | 2.52 | 2.10 |
| Down Beta | 1.06 | 2.68 | -1.10 | 2.35 | 0.93 | 0.97 |
| Up Capture | 346% | 41% | -123% | -42% | 7% | 13% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 13 | 21 | 50 | 89 | 293 |
| Down Capture | 263% | 269% | 110% | 104% | 157% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 14 | 28 | 40 | 73 | 156 | 442 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WORX | |
|---|---|---|---|---|
| WORX | -64.0% | 147.1% | -0.07 | - |
| Sector ETF (XLV) | 9.9% | 17.4% | 0.38 | 15.2% |
| Equity (SPY) | 16.5% | 19.4% | 0.66 | 20.6% |
| Gold (GLD) | 81.3% | 25.7% | 2.29 | -2.1% |
| Commodities (DBC) | 13.4% | 16.9% | 0.58 | 4.5% |
| Real Estate (VNQ) | 7.3% | 16.6% | 0.25 | 15.6% |
| Bitcoin (BTCUSD) | -20.2% | 44.9% | -0.37 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WORX | |
|---|---|---|---|---|
| WORX | -60.8% | 142.5% | -0.08 | - |
| Sector ETF (XLV) | 8.7% | 14.5% | 0.41 | 10.3% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 12.3% |
| Gold (GLD) | 23.5% | 17.1% | 1.12 | 0.6% |
| Commodities (DBC) | 10.6% | 19.0% | 0.44 | 3.0% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.18 | 8.2% |
| Bitcoin (BTCUSD) | 4.5% | 57.0% | 0.30 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WORX | |
|---|---|---|---|---|
| WORX | -52.7% | 207.1% | 0.17 | - |
| Sector ETF (XLV) | 11.1% | 16.5% | 0.56 | 4.0% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 5.6% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.7% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | 6.1% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | -0.5% |
| Bitcoin (BTCUSD) | 66.2% | 66.8% | 1.06 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 10/11/2024 | 10-Q |
| 03/31/2024 | 10/10/2024 | 10-Q |
| 12/31/2023 | 09/24/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 04/17/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.